These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 19853058)

  • 21. Evaluations of organ system development in juvenile toxicology testing.
    Robinson K
    Reprod Toxicol; 2008 Sep; 26(1):51-3. PubMed ID: 18595655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.
    Agoram BM; Martin SW; van der Graaf PH
    Drug Discov Today; 2007 Dec; 12(23-24):1018-24. PubMed ID: 18061880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and submission of a nonclinical (pharmacology/toxicology) CANDA.
    Coleman JB; Wise LD; Greenberg WP; Orfe D; Jarossy N; Eydelloth RS; Peter CP; Spence S; Lankas GR
    Regul Toxicol Pharmacol; 1995 Aug; 22(1):46-53. PubMed ID: 7494902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
    Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM
    Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
    Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
    Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs.
    Colbert A; Umble-Romero A; Prokop S; Chow VF; Wong T; DeSimone D; Zhou L; Pederson S
    MAbs; 2014; 6(5):1178-89. PubMed ID: 25517303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals.
    Vargas HM; Amouzadeh HR; Engwall MJ
    Expert Opin Drug Saf; 2013 Jan; 12(1):91-102. PubMed ID: 23170873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Appropriate use of recovery groups in nonclinical toxicity studies: value in a science-driven case-by-case approach.
    Pandher K; Leach MW; Burns-Naas LA
    Vet Pathol; 2012 Mar; 49(2):357-61. PubMed ID: 21810619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety Pharmacology Evaluation of Biopharmaceuticals.
    Amouzadeh HR; Engwall MJ; Vargas HM
    Handb Exp Pharmacol; 2015; 229():385-404. PubMed ID: 26091648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
    Whitebread S; Hamon J; Bojanic D; Urban L
    Drug Discov Today; 2005 Nov; 10(21):1421-33. PubMed ID: 16243262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune function tests for hazard identification: a paradigm shift in drug development.
    Gore ER
    Basic Clin Pharmacol Toxicol; 2006 Apr; 98(4):331-5. PubMed ID: 16623854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Points to consider" regarding safety assessment of biotechnology-derived pharmaceuticals in non-clinical studies (English translation).
    Nakazawa T; Kai S; Kawai M; Maki E; Sagami F; Onodera H; Kitajima S; Inoue T
    J Toxicol Sci; 2004 Dec; 29(5):497-504. PubMed ID: 15729005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The timing of preclinical toxicological studies: pharmaceutical company approaches to toxicity testing in support of initial clinical investigations.
    Parkinson C; Thomas KE; Lumley CE
    Regul Toxicol Pharmacol; 1996 Apr; 23(2):162-72. PubMed ID: 8661335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.
    Brennan FR; Andrews L; Arulanandam AR; Blumel J; Fikes J; Grimaldi C; Lansita J; Loberg LI; MacLachlan T; Milton M; Parker S; Tibbitts J; Wolf J; Allamneni KP
    Regul Toxicol Pharmacol; 2018 Oct; 98():98-107. PubMed ID: 30026135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonclinical vehicle use in studies by multiple routes in multiple species.
    Gad SC; Cassidy CD; Aubert N; Spainhour B; Robbe H
    Int J Toxicol; 2006; 25(6):499-521. PubMed ID: 17132609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical cardiovascular safety evaluations of biologics: optimizing the approach and follow-up.
    Hondeghem L; De Clerck F
    BioDrugs; 2012 Oct; 26(5):275-82. PubMed ID: 22909102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plant natural products: back to the future or into extinction?
    McChesney JD; Venkataraman SK; Henri JT
    Phytochemistry; 2007 Jul; 68(14):2015-22. PubMed ID: 17574638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of animal models of human disease for nonclinical safety assessment of novel pharmaceuticals.
    Morgan SJ; Elangbam CS; Berens S; Janovitz E; Vitsky A; Zabka T; Conour L
    Toxicol Pathol; 2013; 41(3):508-18. PubMed ID: 22968286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of biosimilars--pharmacokinetic and pharmacodynamic considerations.
    Wang YM; Chow AT
    J Biopharm Stat; 2010 Jan; 20(1):46-61. PubMed ID: 20077248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.